Jubilant Ingrevia Approves Binding Term Sheet To Acquire 40% Stake In Zettaone For ₹189.2 Crore

Market snapshot: The Board of Directors of Jubilant Ingrevia Limited has approved the entry into a binding term sheet to acquire a 40% strategic equity stake in Zettaone Technologies India Private Limited for an estimated cash consideration of ₹189.2 crore. This proposed strategic investment aligns with the company's Pinnacle growth strategy, facilitating its expansion into the Electronics Development and Manufacturing Services (EDMS) and semiconductor value chain.

Data Snapshot

• Jubilant Ingrevia is acquiring a 40% strategic equity stake in Zettaone Technologies India Private Limited for ₹189.2 crore.
• Zettaone Technologies reported a turnover of ₹98.1 crore in FY 25-26, up from ₹79.1 crore in FY 24-25 and ₹51.1 crore in FY 23-24.
• The transaction is expected to close by September 2027 via a 100% cash consideration.

What's Changed

• Zettaone's turnover grew to ₹98.1 crore in FY 25-26 from ₹79.1 crore in FY 24-25, representing a year-on-year increase of approximately 24% (derived: ₹98.1 cr vs ₹79.1 cr).
• Jubilant Ingrevia expands its traditional Specialty Chemicals portfolio directly into the deep-tech electronics and semiconductor engineering space.

Key Takeaways

• Strategic EDMS Play: The acquisition gives Jubilant Ingrevia an active platform in Electronics Development and Manufacturing Services (EDMS), serving critical sectors like aerospace, defense, and automotive.
• Robust Target Growth: Zettaone Technologies demonstrates strong top-line momentum, with turnover rising from ₹51.1 crore in FY 23-24 to ₹98.1 crore in FY 25-26.
• Pinnacle Transformation: The investment is key to Jubilant Ingrevia's Pinnacle growth strategy, bridging custom manufacturing (CDMO) capabilities with hardware engineering.

SAHI Perspective

This acquisition represents a highly calculated pivot by Jubilant Ingrevia. By stepping into the electronics hardware design and semiconductor value chain through Zettaone, Jubilant moves beyond its core specialty chemical footprint. Given their existing CDMO capabilities, this partnership allows them to provide an integrated design-to-delivery model for semiconductor and aerospace customers, tapping into India's growing domestic electronics ecosystem.

Market Implications

The move is expected to be viewed positively by the market as it introduces a high-growth, high-margin electronic design vertical. It enhances the company's valuation multiple by shifting the business profile from a pure-play chemical manufacturing company to an integrated deep-tech and hardware engineering player.

Trading Signals

Market Bias: Bullish

The strategic entry into EDMS and semiconductors via a growing target (₹98.1 crore turnover in FY26) enhances the long-term growth profile under the Pinnacle program. Additionally, the strong Q1 FY27 results (revenue up 25% YoY to ₹1,300 crore) support positive underlying financial momentum.

Overweight: Chemical Manufacturing, Electronics Manufacturing, Semiconductors

Trigger Factors:

• Successful completion of the transaction by the September 2027 deadline.
• Integration of Zettaone's capabilities to capture joint CDMO and hardware design contracts.
• Quarterly operational earnings performance under the Specialty Chemicals segment.

Time Horizon: Medium-term (3-12 months)

Industry Context

India's semiconductor and electronics manufacturing services (EMS) industries are experiencing strong secular tailwinds, driven by government incentives and global supply chain diversification. Specialty chemical players with established industrial CDMO networks, like Jubilant Ingrevia, are leveraging engineering-led acquisitions to build multi-disciplinary industrial platforms.

Key Risks to Watch

• Execution and integration risks associated with entering a non-core hardware engineering business.
• Extended transaction timeline with the deal expected to close by September 2027.
• Intense competition and evolving technology cycles within the EDMS and aerospace segments.

Recent Developments

Jubilant Ingrevia reported robust performance for Q1 FY27 (ended June 30, 2026), with consolidated revenue up 25.28% YoY to ₹1,300.27 crore and net profit up 40.91% YoY to ₹105.82 crore. EBITDA grew 36.53% YoY to ₹209.30 crore, supported by strong performance in Specialty Chemicals and a recovery in Chemical Intermediates.

Closing Insight

Jubilant Ingrevia's strategic stake in Zettaone is a bold step towards multi-sector industrial scaling. Integrating chemical synthesis with hardware design creates a unique value proposition that is well-aligned with the broader industrial electronics shift.

High Performance Trading with SAHI.